Free Trial
NASDAQ:MREO

Mereo BioPharma Group (MREO) Stock Price, News & Analysis

Mereo BioPharma Group logo
$2.88 +0.01 (+0.17%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$2.88 0.00 (0.00%)
As of 07/3/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mereo BioPharma Group Stock (NASDAQ:MREO)

Key Stats

Today's Range
$2.78
$2.89
50-Day Range
$2.14
$2.88
52-Week Range
$1.58
$5.02
Volume
799,203 shs
Average Volume
1.09 million shs
Market Capitalization
$457.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.60
Consensus Rating
Buy

Company Overview

Mereo BioPharma Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

MREO MarketRank™: 

Mereo BioPharma Group scored higher than 36% of companies evaluated by MarketBeat, and ranked 666th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Mereo BioPharma Group has only been the subject of 1 research reports in the past 90 days.

  • Read more about Mereo BioPharma Group's stock forecast and price target.
  • Earnings Growth

    Earnings for Mereo BioPharma Group are expected to decrease in the coming year, from ($0.03) to ($0.04) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mereo BioPharma Group is -41.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mereo BioPharma Group is -41.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mereo BioPharma Group has a P/B Ratio of 7.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mereo BioPharma Group's valuation and earnings.
  • Percentage of Shares Shorted

    5.30% of the float of Mereo BioPharma Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Mereo BioPharma Group has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Mereo BioPharma Group has recently decreased by 5.46%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Mereo BioPharma Group does not currently pay a dividend.

  • Dividend Growth

    Mereo BioPharma Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.30% of the float of Mereo BioPharma Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Mereo BioPharma Group has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Mereo BioPharma Group has recently decreased by 5.46%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Mereo BioPharma Group this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for MREO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of Mereo BioPharma Group is held by insiders.

  • Percentage Held by Institutions

    62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mereo BioPharma Group's insider trading history.
Receive MREO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter.

MREO Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Mereo BioPharma Group plc (MREO): A Bull Case Theory
See More Headlines

MREO Stock Analysis - Frequently Asked Questions

Mereo BioPharma Group's stock was trading at $3.50 at the start of the year. Since then, MREO shares have decreased by 17.9% and is now trading at $2.8750.

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01.

Mereo BioPharma Group (MREO) raised $49 million in an initial public offering (IPO) on the week of April 23rd 2018. The company issued 2,800,000 shares at $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.

Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON), Jabil (JBL) and Builders FirstSource (BLDR).

Company Calendar

Last Earnings
5/13/2025
Today
7/05/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MREO
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.60
High Stock Price Target
$10.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+164.3%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.25 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10 million
Price / Cash Flow
N/A
Book Value
$0.39 per share
Price / Book
7.37

Miscellaneous

Free Float
150,255,000
Market Cap
$457.13 million
Optionable
Optionable
Beta
0.46
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:MREO) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners